Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Date:3/20/2012

share, compared with a net loss of $14.3 million, or $21.84 per share, for the same period in 2010.  Common shares used in calculating basic and diluted earnings per share were 17,345,000 for the year ended December 31, 2011 compared to 657,000 common shares for the year ended December 31, 2010.

As of December 31, 2011, AcelRx had cash, cash equivalents and investments of $35.8 million, compared to $32.0 million at September 30, 2011 and $3.7 million at December 31, 2010.  In February 2011, AcelRx completed its initial public offering, resulting in net proceeds to AcelRx of $34.9 million.  In June 2011, AcelRx entered into a $20.0 million secured loan agreement with Hercules Technology Growth Capital, or Hercules.  Upon execution of the agreement, AcelRx received $10.0 million in the first tranche of the loan and, in December 2011, AcelRx drew down the second $10.0 million tranche of the loan.

"During the last quarter of 2011 and into the first quarter of 2012, AcelRx completed system verification testing, software validation testing and reprocessing validation testing of our ARX-01 device, in addition to filing a new IND for our ARX-04 product candidate.  In early March 2012, AcelRx accomplished a major milestone with the initiation of our first Phase 3 efficacy and safety study for ARX-01 for the treatment of post-operative pain following open abdominal surgery. Shortly, we will be initiating the second Phase 3 study, an active comparator study comparing ARX-01 to the standard of care. These studies, along with the third and final Phase 3 study to support an NDA for ARX-01 due to start in the second half of this year, will set up a very exciting 2012 with data from all three studies expected by early 2013," said Richard King, President and CEO of AcelRx.

Development Update

  • In early March 2012, AcelRx initiated the first of three planned ARX-01 Phase 3 studies. This study is a randomized, double-blind, p
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
    2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
    3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
    4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
    5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
    6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
    7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
    8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
    11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/20/2014)... issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health Canada, ... mg/metered dose due to the product missing the "dip tube," ... A missing "dip tube" could pose a potential problem with ... lead patients to believe they are receiving the nitroglycerin, when ... nitroglycerin could place them at risk for either a delay ...
    (Date:9/19/2014)... , Sept. 19, 2014 Medical ... forging relationships with key opinion leaders (KOLs) who ... competition. Despite the critical nature of the MSL ... challenges, including altering the landscape for creating and ... According to research, the oversight responsibility for the ...
    (Date:9/19/2014)... Harwood Feffer LLP ( www.hfesq.com ) is ... PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... its fiduciary duties to shareholders or violated the federal ... Company disclosed: "On September 11, 2014, [PDL] was orally ... Young LLP ("EY"), that it was resigning effective September ...
    Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
    ... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the ... commercialization of its proprietary stent platform technology, today announced that ... ended September 30, 2011 with the U.S. Securities and Exchange ... Year-to-Date Highlights Year-to-date shipment ...
    ... The new harder to crush version of OxyContin® has ... research revealed at a conference of law enforcement officers ... Prevention (CDC) announced that every day 100 people die ... prescription opioid pain relievers. A new formulation of the ...
    Cached Medicine Technology:InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 2InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 3InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 4InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 5InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 6InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 7InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 8InspireMD Reports Record Third Quarter 2011 Operating and Financial Results and Strategic Update 9New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
    (Date:9/20/2014)... Ticket Down is a reputable source ... popular ticket exchange is offering their customer appreciation promo code ... next step in the entertainment business. The 21-year-old from Boca ... and entertainment business, but is closing in on “Pop Diva” ... album, will hit the road next year on the “Honeymoon ...
    (Date:9/20/2014)... 2014 On Monday, September 22, Loma ... cancer research grant from Hyundai Hope on Wheels at ... Hospital located on 11234 Anderson St., in Loma Linda. ... Payne, Associate Professor at Loma Linda University and Director ... in children. , Loma Linda University Medical ...
    (Date:9/20/2014)... York, New York (PRWEB) September 20, 2014 ... filings continue to grow in federal court, Bernstein ... Food & Drug Administration (FDA) have voted overwhelmingly ... low testosterone in men be subjected to further ... According to a report published on September 18th ...
    (Date:9/20/2014)... 2014 The print component of ... of the Calgary Herald, with a circulation of ... 270,000. The digital component is distributed nationally through ... network of top news sites and partner outlets. ... visit http://www.worklifebalanceinfo.ca . , The publication features ...
    (Date:9/20/2014)... 20, 2014 Lifeinsurancequoteterm.net has released ... no medical exam life insurance plan provides for vulnerable ... family members should be a top priority for every ... insurance without taking medical examinations and visiting a doctor. ... medical examinations will provide coverage up to $300,000, but ...
    Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2
    ... research led by a psychologist at the University of Georgia ... understanding of craving for alcohol and other drugs. This ... values a drug is fairly new, but according to the ... contribute to identifying more effective ways to defeat addictions. ...
    ... HealthDay Reporter , TUESDAY, July 13 (HealthDay News) ... survive the original cancer are at high risk of ... and stroke likely caused by the cancer treatment itself, ... cancer, many have long-term risks of dying prematurely from ...
    ... guidelines on recommended vitamin D intake have been published this ... Association Journal ( CMAJ ). Dr. David Hanley, ... member of Osteoporosis Canada,s (OC) Scientific Advisory Council, is the ... "OC,s current recommendations on vitamin D intake for Canadians ...
    ... By Amanda Gardner HealthDay Reporter , TUESDAY, ... the safety of controversial diabetes drug Avandia, members of the ... skeptical of much of the data presented. A decision ... The hearing has coincided with news that the drug,s ...
    ... regarding treatment following breast-conserving surgery for patients diagnosed with ... of discussion and confusion for patients and physicians alike. ... risk of local recurrence in the breast is high. ... treatment. While both treatments have been proven to ...
    ... protein already used to treat diseases like multiple sclerosis, hepatitis ... patients, UT Southwestern Medical Center researchers have found. ... of a population of immune cells known to cause asthma. ... called T helper 2 cells, or Th2 cells. Under normal ...
    Cached Medicine News:Health News:New analysis may help clarify the role of craving in addiction 2Health News:New analysis may help clarify the role of craving in addiction 3Health News:Childhood Cancer Survivors at Risk of Premature Death 2Health News:Childhood Cancer Survivors at Risk of Premature Death 3Health News:New vitamin D guidelines 2Health News:FDA Panel Seems Skeptical Over Key Avandia Data 2Health News:FDA Panel Seems Skeptical Over Key Avandia Data 3Health News:FDA Panel Seems Skeptical Over Key Avandia Data 4Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Interferon might help asthma patients breathe easier, UT Southwestern study suggests 2
    0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
    3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
    For use in implant arthroplasty associated with comminuted fractures, or rheumatoid, degenerative or post-traumatic disease of the radial head. Designed for higher demand patients requiring superior ...
    This legless table has adjustable height and round post. Pad sold separately....
    Medicine Products: